NCT00325897View on ClinicalTrials.gov

Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease

NACompletedINTERVENTIONAL
Enrollment

1,142

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Macrolide Antibiotic (Azithromycin)

Azithromycin (daily capsule, 250 mg for 12 months)

DRUG

Placebo

Placebo taken on a daily basis

Trial Locations (10)

15213

University of Pittsburgh, Pittsburgh

19140

Temple University, Philadelphia

21201

University of Maryland Baltimore, Baltimore

35249

University of Alabama at Birmingham, Birmingham

48109

University of Michigan, Ann Arbor

55440

Minnesota Veterans Research Inst., Minneapolis

80262

Denver City-County Health/Hospitals Dept., Denver

90502

Harbor-UCLA Research & Education Inst., Torrance

94143

University of California at San Francisco, San Francisco

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Minnesota

OTHER

NCT00325897 - Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter